ACApeng Chen

Apeng Chen

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Apeng Chen has a total of 281 co-authors. Here are the top co-authors by number of shared publications:

  • Baoli Hu

    Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, USA

    21 shared publications
  • Qianghu Wang

    Institute for Brain Tumours, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China

    21 shared publications
  • Xiangwei Xiao

    Department of Surgery, Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, USA

    21 shared publications
  • Xiuxing Wang

    National Health Commission Key Laboratory of Antibody Techniques, Department of Cell Biology, Jiangsu Provincial Key Laboratory of Human Functional Genomics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China

    21 shared publications
  • Yinan Jiang

    John G. Rangos Sr. Research Center, University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

    21 shared publications
  • Fengqi Zhou

    Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    20 shared publications

Latest Publications

  • Mast Cell‐Targeted Gas Therapeutic Strategy: Intelligent H 2 S‐Donor Nano‐Stabilizer for the Long‐Term Treatment of Allergic Diseases In Vivo

    by Qian Shen, Chan Fu, Xiaoyu Song, Yangyang Pu, Yao Wang, Xiang Che, Apeng Chen, Man Tian, Lin Li, Changmin Yu

    Allergic diseases driven by dysregulated mast cell activation remain a major clinical challenge due to the repeated long‐term dosing and severe side effects of current small‐molecule stabilizers. Gas therapy offers a promising alternative owing to its high biocompatibility, minimal toxicity, and stimulus‐responsive release. Hydrogen sulfide (H 2 S), an endogenous gas mediator involved in inflammatory regulation, has not yet been explored for the treatment of allergic inflammation. Herein, a mast cell‐targeted H 2 S gas therapeutic strategy was developed for the long‐term treatment of allergic diseases. Biodegradable mesoporous organosilica nanoparticles incorporating tetrasulfide bridges were rationally designed, loaded with sodium cromoglicate, and surface‐modified with hyaluronic acid (HA) to construct the nano‐stabilizer ( S MSNs@SC@HA ). HA coating enabled mast cell targeting and prevented premature drug leakage. Intracellular glutathione triggered sustained (>24 h) H 2 S release via tetrasulfide bond cleavage, suppressing mast cell degranulation through antioxidative effects and AMP‐activated kinase (AMPK) activation, while simultaneously inducing carrier degradation and controlled drug release. This system represents the first H 2 S‐donating nanoplatform for targeted mast cell delivery, achieving synergistic anti‐allergic efficacy. In vivo studies in passive cutaneous anaphylaxis and allergic asthma models demonstrated high therapeutic efficacy, prolonged treatment duration, and negligible inflammatory side effects, highlighting its strong potential for clinical translation.

  • Open Access

    Using interpretable machine learning models to predict the occurrence of severe influenza in hospitalized children: a retrospective cohort study

    by Jinhuan Wu, Wenxian Qian, Shuqin Xie, Yi Yan, Gang Chen, Ye Wang, Xing Liu, Xiuchang Ma, Yuchen Du, Yaowen Liang, et al.

    Influenza, a prevalent disease, significantly threatens public health. Accurately predicting severe influenza occurrences is crucial for developing persona

  • The spatiotemporal evolution of radiation resistance in glioblastoma

    by Lingxiang Wu, Lei Cheng, Bin Huang, Runheng Huang, Ravesanker Ezhilarasan, Junxia Zhang, Wei Wu, Guojing Wu, Benqing Yu, Lindsey D Goodman, et al.

    Background: Although radiation therapy (RT) remains one of the most effective treatments for patients with the lethal brain tumor glioblastoma (GBM), quite a number of patients show resistance or relapse shortly after RT. There is an urgent need to uncover the temporal and spatial dynamics of RT resistance during tumor progression and treatment. Methods: The radio-resistance signature score (RRSS) was calculated by utilizing glioma sphere-forming cells (GSCs), which recapitulate the transcriptomic landscape of GBM. Results: RRSS can assess the RT response on both cell lines and GBM patients. Both transdifferentiated and irradiated glioma cells show increased radiation resistance, demonstrating that the recurrent GBM may acquire resistance along with cell differentiation and selective advantage during treatment. Moreover, RRSS of the marginal tumors is found to be higher than that of core tumors (Wilcoxon’s rank-sum test, P-value <.01). The infiltration of macrophages was significantly associated with radiation resistance (P-value <.01), which was further validated by single-cell RNAseq-based experiments and clonogenic assays. Moreover, we demonstrated that IL1B, a pro-inflammatory cytokine secreted by macrophages, could enhance the radiation resistance of tumor cells. Conclusions: Our study revealed the spatiotemporal evolution of radiation resistance of GBM and shed light on the development of novel adjuvant therapeutic strategies.


  • Open Access

    Epithelial Fatty ACID Oxidation Dysfunction Promotes Palmitoylcarnitine-driven Airway Remodeling in Bronchiolitis Obliterans

    by Xing Liu, Ye Wang, Min Zhang, Yahui Cao, Mingxin Ni, Xiaoyu Song, Linlin Li, Qing Han, Min Da, Lili Zuo, et al.

    Background: Bronchiolitis obliterans (BO) is a devastating chronic airway disease characterised by irreversible bronchiolar obstruction and progressive epithelial remodelling after severe respiratory infection. However, the metabolic mechanisms that determine epithelial repair fate and drive irreversible airway remodelling remain largely unknown. Methods: We integrated spatial metabolomics, quantitative proteomics, transcriptomics, genetically engineered mouse models, and clinical cohort analyses to investigate metabolic alterations associated with epithelial remodelling in BO. Human BO lung tissues and experimental BO models were used to assess fatty acid oxidation (FAO), SLC25A20 expression, and acylcarnitine accumulation. Mechanistic studies examined the effects of palmitoylcarnitine on mitochondrial stress, STING–NF-κB signalling, and epithelial remodelling. Epithelial-specific Slc25a20 deletion and pharmacological STING inhibition were used to determine causality and therapeutic potential. Findings: Epithelial FAO was markedly impaired in BO, accompanied by reduced expression of the mitochondrial carnitine transporter SLC25A20 and accumulation of long-chain acylcarnitines, particularly palmitoylcarnitine, in human BO tissues and experimental models. Reduced SLC25A20 expression during adenovirus pneumonia was associated with subsequent BO development. Palmitoylcarnitine induced mitochondrial stress, activated STING–NF-κB signalling, and promoted an aberrant epithelial remodelling programme characterised by increased KRT17, KRT5, and SNAI2 expression. Epithelial-specific Slc25a20 deletion reproduced these metabolic and pathological alterations and exacerbated diacetyl-induced BO, whereas pharmacological inhibition of STING restored epithelial homeostasis and attenuated airway remodelling. Interpretation: Disrupted epithelial FAO caused by SLC25A20 deficiency promotes palmitoylcarnitine accumulation and activates STING–NF-κB signalling, thereby driving maladaptive epithelial repair and airway remodelling in BO. These findings identify the SLC25A20–palmitoylcarnitine–STING–NF-κB axis as a metabolic mechanism linking mitochondrial dysfunction to epithelial repair failure and provide a rationale for targeting this pathway to prevent or attenuate irreversible airway remodelling after severe respiratory infection.

  • Open Access

    SLC25A20 promotes tumor growth by reprogramming energy metabolism in lung adenocarcinoma

    by Xing Liu, Xiaoyu Song, Cong Gan, Ye Wang, Mingxin Ni, Min Zhang, Shaodi Wen, Yahui Cao, Changhua Yi, Man Tian, et al.

    Accumulating evidence has shown that the dysfunction of mitochondria, the multifunctional organelles in various cellular processes, is a pivotal event in the development of various diseases, including human cancers. The molecular alterations in tumors that promote metabolic diversity and distinct targetable dependencies remain poorly defined. The mitochondrial transporter SLC25A20, also known as carnitine-acylcarnitine translocase (CACT), is crucial for fatty acid β-oxidation (FAO) by importing acylcarnitines into the mitochondrial matrix. Here, we demonstrate that SLC25A20 is significantly upregulated in lung adenocarcinoma (LUAD) tissues and cells, and its expression correlates with poor patient survival. Gain- and loss-of-function experiments reveal that SLC25A20 promotes tumor cell proliferation, survival, migration, and invasion by enhancing FAO-associated mitochondrial bioenergetics and suppressing apoptosis. Mechanistically, SLC25A20-mediated FAO maintains mitochondrial function and supports oxidative phosphorylation (OXPHOS), thereby sustaining tumor bioenergetics and redox homeostasis. Pharmacological inhibition or genetic silencing of SLC25A20 impairs tumor growth in vivo. These findings establish SLC25A20 as a key metabolic driver in LUAD and suggest it may be a therapeutic target.

  • Open Access

    tRNA-derived small RNAs in pulmonary diseases: Regulatory functions and clinical prospects

    by Ye Wang, Xiaoyu Song, Ge Ma, Xing Liu, Cong Gan, Apeng Chen, Man Tian, Xu Han


  • Open Access

    Analysis of Risk Factors and Development of a Predictive Nomogram for Bronchiolitis Obliterans in Children With Severe Adenovirus Pneumonia: A Retrospective Study

    by Gang Chen, Xing Liu, Xiuchang Ma, Jinhuan Wu, Yaowen Liang, Yuchen Du, Xiaoyu Song, Wenxian Qian, Apeng Chen, Changhua Yi, et al.

    Background: Bronchiolitis obliterans (BO) is a rare chronic pulmonary condition in pediatric patients, characterized by irreversible fibrotic constriction of the small airways. This study aims to analyze the risk factors for BO caused by severe adenovirus pneumonia (SAP) and to develop a nomogram model for personalized prediction. Methods: We retrospectively analyzed 251 children with SAP admitted to the Children’s Hospital of Nanjing Medical University between January 2017 and March 2024. Among them, 77 were classified into the BO group and 174 into the non‐BO group. A predictive nomogram was developed based on independent risk factors identified through univariate analysis, least absolute shrinkage and selection operator (LASSO) regression, and multivariate logistic regression. Results: Multivariable analysis identified the following independent risk factors for BO: wheezing (odds ratio [OR] = 4.78; 95% confidence interval [CI], (2.00∼11.40); p < 0.001), large lobar consolidation (OR = 8.53; 95% CI, 3.63∼20.02; p < 0.001), length of hospital stay (OR = 1.20; 95% CI, 1.08–1.33; p < 0.001), and duration of fever (OR = 1.20; 95% CI, 1.09–1.32; p < 0.001). Mechanical ventilation showed a trend toward increased risk but did not reach statistical significance (OR = 5.35; 95% CI, 0.74–38.56; p = 0.096). The nomogram demonstrated excellent discriminative ability, with an area under the curve of 0.90 (95% CI: 0.85–0.94). Calibration curves indicated good agreement between predicted and observed outcomes. Decision curve analysis showed a net clinical benefit within a clinically relevant threshold probability range of 0.10–0.70. Conclusions: A nomogram incorporating five independent risk factors—wheezing, duration of fever, length of hospital stay, mechanical ventilation, and large lobar consolidation—was developed to predict BO risk in children with SAP.

  • Open Access

    Combining nanobody generation platform, 3D-printed microfluidic chip, and smartphone detection system for monitoring emerging virus-caused diseases

    by Yanhong Ji, Fengyun Li, Zhaowei Qu, Xiangkun Wang, Pengfei Cui, Guohua Deng, Shaorong Liu, Qiaosheng Pu, Qiyun Zhu, Apeng Chen


  • Open Access

    Host Immune Response to Respiratory Syncytial Virus Infection in Children

    by Gang Chen, Xiuchang Ma, Jinhuan Wu, Yi Yan, Wenxian Qian, Apeng Chen, Changhua Yi, Man Tian

    Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory diseases in children, especially in infants. The immune responses induced by RSV infection are a fairly complex process that can contribute significantly to disease severity. Despite decades of research on RSV, many immune mechanisms remain to be explored. A full exploration of these immune responses can contribute to the discovery of new therapeutic and prophylactic approaches. Despite significant advancements in vaccine development and monoclonal antibody research, effective therapeutic options remain limited. This review focuses on how the immune system reacts when children contract the respiratory syncytial virus. We describe the biological characteristics of RSV, viral‐cell interactions, immune evasion, innate immunity (including pattern recognition receptors and inflammatory cells), and adaptive immunity (including CD4+ and CD8+ T cells and humoral immune response). Understanding the complicated immune response to RSV infection is essential for developing effective interventions and vaccine developments. This review aims to deepen the understanding of the impact of Respiratory Syncytial Virus (RSV) on the immune system and to contribute to the advancement of practical therapeutic strategies.


  • Open Access

    Retrospective Analysis of Severe Fever With Thrombocytopenia Syndrome and Construction of a Nomogram Prediction Model for Mortality Risk Factors

    by Gang Chen, Yuchen Du, Xiuchang Ma, Yaowen Liang, Apeng Chen, Jie Wei, Jinhuan Wu, Wenxian Qian, Shuqin Xie, Yi Yan, et al.

    Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging zoonotic infectious disease caused by the SFTS virus and is characterized by a high mortality rate. The primary objective of this study was to investigate high-mortality risk factors in SFTS and to create a nomogram model for personalized prediction. Methods: A total of 523 patients with SFTS who were admitted to the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, between January 2020 and December 2023 were retrospectively analyzed: 75 cases were classified in the death group and 448 cases in the survival group. Development of a predictive nomogram model was based on the independent risk factors that were stepwise screened through univariate analysis, LASSO analysis (least absolute shrinkage and selection operator), and multivariate logistic regression analysis. Results: Based on stepwise variable screening by univariate analysis, LASSO analysis, and multivariate logistic regression, the following were independent mortality risk factors in patients with SFTS: age (odds ratio [OR], 1.06; 95% CI, 1.03–1.10; P < .001), hemorrhagic symptoms (OR, 3.39; 95% CI, 1.31–8.78; P = .012), neurologic symptoms (OR, 4.89; 95% CI, 2.72–8.77; P < .001), platelet count (OR, 0.99; 95% CI, .98–.99; P = .045), prothrombin time (OR, 1.32; 95% CI, 1.11–1.56; P = .001), activated partial thromboplastin time (OR, 1.02; 95% CI, 1.01–1.03; P = .007), and viral load ≥107copies/mL (OR, 2.66; 95% CI, 1.36–5.20; P = .004). The area under the curve (0.87; 95% CI, .832–.909) showed excellent predictive power. Calibration curves showed the accuracy of the assessed nomograms. Decision curve analysis results showed a greater net benefit when the threshold probability of patient death was between 0.02 and 0.75. Conclusions: A nomogram model consisting of 7 risk factors was successfully constructed, which can be used to predict SFTS mortality risk factors early.